Efficacy and safety of 10% HES 130/0.4 versus 10% HES 200/0.5 for plasma volume expansion in cardiac surgery patients

Minerva Medica

Volumn 103, Issue 2, 2012, Pages 111-122

  Ertmer, C ^a   Wulf, H ^b   Van Aken, H ^a   Friederich, P ^c   Mahl, C ^d   Bepperling, F ^d   Westphal, M ^a,d   Gogarten, W ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Fresenius Kabi Deutschland GmbH   (Germany)

Author keywords

Blood coagulation; Cardiopulmonary bypass; Fluid therapy; Thoracic surgery

Indexed keywords

CREATININE; HETASTARCH; STERIL; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD GROUP; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART SURGERY; HEMOSTASIS; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIOPERATIVE PERIOD; PLASMA VOLUME; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

BLOOD COAGULATION TESTS; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FACTOR VIII; FEMALE; GERMANY; HEART VALVES; HETASTARCH; HUMANS; MALE; MIDDLE AGED; PLASMA SUBSTITUTES; PROSPECTIVE STUDIES; VON WILLEBRAND FACTOR;

EID: 84862734858     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Laxenaire MC, Charpentier C, Feldman L. [Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study]. Ann Fr Anesth Reanim 1994;13:301-10.
2. Jungheinrich C, Neff TA. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 2005;44:681-99.
3. Waitzinger J, Bepperling F, Pabst G, Opitz J, Muller M, Francois Baron J. Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers. Clin Drug Investig 1998;16:151-60.
4. Leuschner J, Opitz J, Winkler A, Scharpf R, Bepperling F. Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 2003;4:331-8.
5. Standi T, Burmeister MA, Schroeder F, Currlin E, Schulte am Esch J, Freitag M. Hydroxyethyl starch (HES) 130/0.4 provides larger and faster increases in tissue oxygen tension in comparison with prehemodilution values than HES 70/0.5 or HES 200/0.5 in volunteers undergoing acute normovolemic hemodilution. Anesth Analg 2003;96:936-43, table of contents.
6. Waitzinger J, Bepperling F, Pabst G, Opitz J. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 2003; 4: 149-57.
7. Felfernig M, Franz A, Braunlich P, Fohringer C, Kozek-Langenecker SA. The effects of hydroxyethyl starch solutions on thromboelastography in preoperative male patients. Acta Anaesthesiol Scand 2003;47:70-3.
8. Waitzinger J, Bepperling F, Fackelmayer A, Opitz J, Pabst G. Effect of HES 130/0.4 10% on blood and plasma volume [Abstract]. 99th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. New Orleans, USA, 1998; p. 210/PIII-10.
9. Rudolf J. Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 2002;14:33-41.
10. Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W et al. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000;47:1207-15.
11. Kasper SM, Meinert P, Kampe S, Gorg C, Geisen C, Mehlhorn U et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 2003,99:42-7.
12. Kuitunen A, Suojaranta-Ylinen R, Kukkonen S, Niemi T. A comparison of the hemodynamic effects of 4% succinylated gelatin, 6% hydroxyethyl starch (200/0.5) and 4% human albumin after cardiac surgery. Scand J Surg 2007;96:72-8.
13. Sirvinskas E, Sneider E, Svagzdiene M, Vaskelyte J, Raliene L, Marchertiene I et al. Hypertonic hydroxyethyl starch solution for hypovolemia correction following heart surgery. Perfusion 2007;22:121-7.
14. Greenburg AG, Kim HW. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. J Am Coll Surg 2004;198:373-83; discussion 84-5.
15. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001;92:855-62.
16. Jungheinrich C, Sauermann W, Bepperling F, Vogt NH. Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs R D 2004,5:1-9.
17. World Medical Association: Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Tokyo, 2004; 55th WMA General Assembly.
18. EMEA. Points to consider on switching between superiority and non-inferiority. 2000; CPMP/EWP/482/99.
19. Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley AB et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003; 1: 2191-7.
20. Sukhu K, Poovalingam V, Mahomed R, Giangrande PL. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin Lab Haematol 2003;25:247-9.
21. Vanhoonacker J, Ongenae M, Vanoverschelde H, Donadoni R. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for cardiopulmonary bypass priming: the effects on postoperative bleeding and volume expansion needs after elective CABG. Acta Anaesthesiol Belg 2009,60.91-7.
22. Tiryakioglu O, Yildiz G, Vural H, Goncu T, Ozyazicioglu A, Yavuz S. Hydroxyethyl starch versus Ringer solution in cardiopulmonary bypass prime solutions (a randomized controlled trial). J Cardiothorac Surg 2008;3:45.
23. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K. All medium starches are not the same: influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 1996;36:450-5.
24. Knutson JE, Deering JA, Hall FW, Nuttall GA, Schroeder DR, White RD et al. Does intraoperative hetastarch administration increase blood loss and transfusion requirements after cardiac surgery? Anesth Analg 2000;90:801-7.
25. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997;78:974-83.
26. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564-75.
27. Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008;12:R74.
28. Schortgen F, Girou E, Deye N, Brochard L. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008;34:2157-68.
29. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
30. Treib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K. Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haematol 1996;56:168-72.
31. Nuttall GA, Oliver WC. Con: use of colloids in cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:457-9.
32. Strauss RG, Stansfield C, Henriksen RA, Villhauer PJ. Pentastarch may cause fewer effects on coagulation than hetastarch. Transfusion 1988;28:257-60.
33. Strauss RG, Pennell BJ, Stump DC. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion 2002;42:27-36.
34. Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE et al. Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology 2007;106:1120-7.
35. Konrad CJ, Markl TJ, Schuepfer GK, Schmeck J, Gerber HR. In vitro effects of different medium molecular hydroxyethyl starch solutions and lactated Ringer's solution on coagulation using SONOCLOT. Anesth Analg 2000;90:274-9.
36. Scharbert G, Deusch E, Kress HG, Greher M, Gustorff B, Kozek-Langenecker SA. Inhibition of platelet function by hydroxyethyl starch solutions in chronic pain patients undergoing peridural anesthesia. Anesth Analg 2004;99:823-7, table of contents.
37. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg 2003;96:1453-9, table of contents.
38. Ellger B, Freyhoff J, Van Aken H, Booke M, Marcus MAE. High dose volume replacement using HES 130/0.4 during major surgery. Impact on coagulation and incidence of postoperative itching. Nederlands Tijdschrift voor Anesthesiologie 2006;19:63-8.
39. Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P. Safety of HES 130/0.4 (Voluven(R)) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, parallel-group multicentre trial. Eur J Anaesthesiol 2008;25:986-94.
40. Chong Sung K, Kum Suk P, Mi Ja Y, Kyoung Ok K. Effects of intravascular volume therapy using hydroxyethyl starch (130/0.4) on post-operative bleeding and transfusion requirements in children undergoing cardiac surgery: a randomized clinical trial. Acta Anaesthesiol Scand 2006;50:108-11.
41. Hanart C, Khalife M, De Ville A, Otte F, De Hert S, Van der Linden P. Perioperative volume replacement in children undergoing cardiac surgery: albumin versus hydroxyethyl starch 130/0.4. Crit Care Med 2009;37:696-701.